NCT05930028View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions
Essential HypertensionPrimary Hypercholesterolemia
Interventions
DRUG

Fimasartan

Subjects take the investigational products once a day for 8 weeks.

DRUG

Ezetimibe/Atorvastatin

Subjects take the investigational products once a day for 8 weeks.

DRUG

Fimasartan Placebo

Subjects take the investigational products once a day for 8 weeks.

DRUG

Ezetimibe/Atorvastatin Placebo

Subjects take the investigational products once a day for 8 weeks.

Trial Locations (1)

120-752

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY